Advanced Nuclear Medicine Ingredients

Our goal is to help improve cancer patient outcomes with accessible, targeted radiopharmaceuticals, focussing initially on use of the radionuclide Lutetium-177. Applied Molecular Therapies (AMT) – a leader in the development, manufacture and supply of next generation therapeutic radiopharmaceuticals for cancer treatments in Australia and New Zealand. Cyclotek, a leading radiopharmaceutical manufacturer, is at the forefront of validating new molecular targeted radiopharmaceuticals for the Australian and New Zealand markets. By using accessible targeted radiopharmaceuticals, our goal is to improve cancer patient outcomes. ANSTO, Australia’s knowledge centre for nuclear science and engineering, leverages great science to deliver big outcomes.

We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture or source nca Lu-177 and other radioisotopes of interest. We are dedicated to improving the accessibility and supply security of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem. Global Morpho Pharma is a French start-up company created in 2018 that aims at developing and distributing GMP-grade radioisotopes. Five experts of the nuclear medicine field came together with a common vision about the future of radiotherapeutics and radiotheranostics. In 1995, Pierre-Marie-Lemer became Managing Director of Lemer Pax, a company founded in 1970. The company has been a partner of France’s Atomic Energy Commission (CEA) since its creation. Lemer Pax conceives, designs and manufactures innovative radioprotection solutions for use in the fields of medicine, scientific research, industry and nuclear protection. A historic leader in the French nuclear medicine sector, Lemer Pax is the first company in the world to have designed and developed a mobile unit for the preparation and injection of high energy radiopharmaceuticals.

Our mission is to enable innovative cancer care by establishing theragnostics as a standard treatment option. We are entrepreneurial-spirited, and everyone’s opinions are welcomed and highly valued. Our theragnostic portfolio has a range of products. We offer customised solutions for nuclear medicine, PET, and radiotherapy departments. With 25 years of experience, we feel confident that we work with the best suppliers and products. As the company grows, we still strive to give every one of our customers personal service, including speedy and high-quality communication. S Ahlén Medical Nordic AB (SAM Nordic) works following the European Commission’s Guidelines on Good Distribution Practice (GDP) of medicinal products for human use and is authorised by the Swedish Medical Products Agency to conduct wholesale activities with radiopharmaceuticals. Our partners and suppliers hold GMP certificates and manufacturing licenses from the local Competent Authorities in each country.

Nucleis is a radiopharmaceutical company active in the Nuclear Medicine sector. Nucleis is a spin-off from the University of Liège (Cyclotron Research Center - Belgium) created to outsource the GMP manufacturing and distribution of PET (Positron Emission Tomography) radiopharmaceutical drugs. Nucleis is also a key partner for CMO activities. Nucleis is the MAH (Marketing Authorisation Holder) and Manufacturer of a FDG (Fludeoxyglucose (18F)) MA (Marketing Authorisation) granted in Belgium, The Netherlands, Luxembourg, France and Germany. Nucleis aims at developing a wide portfolio of diagnostic tools in order to support the emergence of innovative therapies. Nucleis is a radiopharmaceutical company, created in June 2017 and has performed a transfer of the business unit (existing team, pharmaceutical certifications, CMO contracts and dedicated manufacturing facilities) from CRC in November 2017 and benefits from over 15 years of experience. Nucleis is a spin-off from the University of Liège (CRC-Cyclotron) created to outsource the GMP manufacturing and distribution of radiopharmaceuticals drugs dedicated to Positron Emission Tomography (PET). Nucleis propose direct sales among Nuclear Medicine department, equipped with a PET-Scan, with Glucotrace (FDG) marketed in Belgium, Netherlands, Luxembourg, France and Germany and also with other drugs with an Investigational Medicine Product dossier (clinical trial).

Founded in 2018, AMNI (Advanced Manufacturing Network Integrators) is an IT company focused on integrating and verifying the supply chains of critical components where authenticity is of high importance. AMNI provides high levels of security, auditability, and compliance to the entire supplier base. AMNI connects producers, distributors, retailers, and customers through verified data and access to real-time information. Our mission is to connect producers, distributors, retailers, and customers through verified data and access to real-time information. With AMNI you can now monitor the quality of your supply chain in real-time. The AMNI platform is a three-sided marketplace for suppliers, manufacturers, and brands. Collaborating with AMNI's expansive network of industry-leading partners, AMNI delivers synergistic solutions that amplify your business potential, foster growth, and accelerate your journey towards achieving strategic goals. The future of supply chains is coming—get ready for the AMNI Network.

Announced plans to build RLT manufacturing capabilities in Sasayama, Japan and Haiyan, Zhejiang, China. Radioligand therapy: delivering now, building for the future. Founded in 2002, AAA has a strong legacy as a pioneer in nuclear medicine. We believe targeted radioligand therapy has the potential to be broadly used in many different tumor types. To help associates, the local leadership team will provide local guidance and support. AAA and Novartis continue to provide additional resources like coaching and learning tools – irrespective of place of work. As the coronavirus (COVID-19) situation continues to evolve, our primary concern at Advanced Accelerators Applications (AAA), a Novartis Company, remains the health and safety of our associates and patients globally. As before, we will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.